| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/25/2009 | EP2037741A1 Compositions and methods relating to novel compounds and targets thereof |
| 03/25/2009 | EP2037740A2 Compositions and methods to enhance reverse cholesterol transport |
| 03/25/2009 | EP2037739A2 Benzyl-substituted quinolone m1 receptor positive allosteric modulators |
| 03/25/2009 | EP2037738A2 Delivery method |
| 03/25/2009 | EP2000540A9 Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer |
| 03/25/2009 | EP2000473A9 Trehalose compound and pharmaceutical comprising the compound |
| 03/25/2009 | EP2000469A9 Acylaminopiperidine compound |
| 03/25/2009 | EP2000152A9 Solid preparation having improved solubility |
| 03/25/2009 | EP1846434B1 NANDROLONE 17ß-CARBONATES |
| 03/25/2009 | EP1841765B1 Imidazo[4,5-c]pyridine compound and method of antiviral treatment |
| 03/25/2009 | EP1824504B1 Antitumor combinations containing vegf-trap and 5fu or one of its derivatives |
| 03/25/2009 | EP1815022A4 Method of determining a cellular response to a biological agent |
| 03/25/2009 | EP1789403B1 N-(phenyl-oxazol-4-ylmethoxymethyl)-cyclohexyl.succinic acid amide derivatives and related compounds which are used as ppar-ligands (peroxisome proliferator activated receptors) for the treatment of hyperlipidaemie and diabetes |
| 03/25/2009 | EP1784389A4 Process for atorvastatin calcium amorphous |
| 03/25/2009 | EP1756063A4 Amido compounds and their use as pharmaceuticals |
| 03/25/2009 | EP1755401A4 Dietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport |
| 03/25/2009 | EP1718624B1 Benzamide derivatives and their use as glucokinase activating agents |
| 03/25/2009 | EP1718258B1 Abuse resistance opioid transdermal delivery device |
| 03/25/2009 | EP1697379B1 Spirocyclic cyclohexane derivatives |
| 03/25/2009 | EP1696931B1 Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| 03/25/2009 | EP1694325A4 Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses |
| 03/25/2009 | EP1682131B9 Cci-779 for treating mantle cell lymphoma |
| 03/25/2009 | EP1681280B1 Novel phenol derivatives and antitrypanosoma preventive/therapeutic agent containing the same as active ingredient |
| 03/25/2009 | EP1664852A4 Method for configuring air-core photonic-bandgap fibers free of surface modes |
| 03/25/2009 | EP1636218B1 Thiazolylpiperidine derivatives as mtp inhibitors |
| 03/25/2009 | EP1635641B1 Mitotic kinesin inhibitors |
| 03/25/2009 | EP1610790A4 Anticancer compounds |
| 03/25/2009 | EP1594885B8 Medicament for inhibiting tumour growth |
| 03/25/2009 | EP1594471B1 Process for manufacturing a dexamethasone-containing formulation for oral administration |
| 03/25/2009 | EP1592680B9 2-phenylpyran-4-one derivatives as selective cox-2 inhibitors |
| 03/25/2009 | EP1578401A4 Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
| 03/25/2009 | EP1555265B1 7-phenyl pyrazolopyridine compounds |
| 03/25/2009 | EP1509201B1 Film-shaped preparations with improved chemical stability containing active substances and method for the production thereof |
| 03/25/2009 | EP1504010B1 Vitamin-mitomycin conjugates |
| 03/25/2009 | EP1476539B1 Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins |
| 03/25/2009 | EP1472228B1 Process for the manufacture of hmg-coa reductase inhibitors |
| 03/25/2009 | EP1460999B1 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof |
| 03/25/2009 | EP1432684B1 Pyridinic sulfonamide derivatives, method of production and use thereof |
| 03/25/2009 | EP1405640B1 Novel immunosuppressants |
| 03/25/2009 | EP1380295B1 Photosensitiser and method for production thereof |
| 03/25/2009 | EP1377579B1 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
| 03/25/2009 | EP1353692B1 Methods and compositions for treatment of ocular neovascularization and neural injury |
| 03/25/2009 | EP1319183B1 Methods and products related to low molecular weight heparin |
| 03/25/2009 | EP1287035B1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 03/25/2009 | EP1242587B1 A NOVEL ISOFORM OF HUMAN cAMP-DEPENDENT PROTEIN KINASE, C ALPHA-s, LOCALIZES TO SPERM MIDPIECE AND THE USE THEREOF |
| 03/25/2009 | EP1221847B1 Methods of enhancing chemotherapy |
| 03/25/2009 | EP1154770B1 Parenteral formulation of piperacillin |
| 03/25/2009 | EP1050301B1 Medicinal compositions containing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
| 03/25/2009 | EP0990391B1 Phytosterol-containing fat composition |
| 03/25/2009 | CN101395228A Quinaldine based semisquaraines and squaraine dyes, process for preparation thereof and use thereof |
| 03/25/2009 | CN101395171A Steroidal compounds as steroid sulphatase inhibitors |
| 03/25/2009 | CN101395170A Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions |
| 03/25/2009 | CN101395168A Galactose derivative,Drug carrier and medicinal composition |
| 03/25/2009 | CN101395161A Thiadiazole compounds and their use in phototherapy |
| 03/25/2009 | CN101395158A Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors |
| 03/25/2009 | CN101395157A Pyrrazole derivatives as sigma receptors antagonists |
| 03/25/2009 | CN101395156A Imidazo[1,2-a]pyridin-3-yl-acetic acid hydrazides, processes for their preparation and pharmaceutical uses thereof |
| 03/25/2009 | CN101395155A Pyridopyrimidinone inhibitors of pi3k alpha |
| 03/25/2009 | CN101395154A 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| 03/25/2009 | CN101395153A Use of adenosine A1 and/or dual A1/A2B agonists for production of medicaments for treating diseases |
| 03/25/2009 | CN101395152A Sigma receptor compounds |
| 03/25/2009 | CN101395150A Phenethanolamine derivatives as beta2 adrenoreceptor agonists |
| 03/25/2009 | CN101395147A 1-(benzo (d) (1,3) dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis |
| 03/25/2009 | CN101395145A Novel heterocyclic cycloalkyl derivatives, method for the preparation thereof, and pharmaceutical compositions containing the same |
| 03/25/2009 | CN101395143A Aza heterocyclics for the treatment of malaria or aids |
| 03/25/2009 | CN101395142A 4-amino-1,5-substituted 1,5-dihydro-imidazol-2-ones |
| 03/25/2009 | CN101395141A Imidazole-based compounds, compositions comprising them and methods of their use |
| 03/25/2009 | CN101395139A Sigma receptor compounds |
| 03/25/2009 | CN101395138A Sigma receptor inhibitors |
| 03/25/2009 | CN101395137A Substituted 2-amino-4-phenyl-dhydroquinolines, method for the production thereof, use thereof as medicaments, and medicaments containing them |
| 03/25/2009 | CN101395136A New pyridin-3-amine derivatives |
| 03/25/2009 | CN101395135A New primary amines |
| 03/25/2009 | CN101395134A 17 beta hsd type 5 inhibitor |
| 03/25/2009 | CN101395133A Sigma receptor compounds |
| 03/25/2009 | CN101395130A Acyclic sulfamide derivatives |
| 03/25/2009 | CN101395104A An improved process for the preparation of armodafinil |
| 03/25/2009 | CN101394898A Glucan compositions |
| 03/25/2009 | CN101394868A Strong immune induction by using combination of adenovirus type-5/type-35 vector and vaccinia virus mva vector |
| 03/25/2009 | CN101394866A Stabilizer for hydrophobic compounds |
| 03/25/2009 | CN101394860A Inhibition of inflammatory cytokine production with tanshinones |
| 03/25/2009 | CN101394858A Intestinal alpha-glucosidase inhibitors and a process for the isolation and use thereof |
| 03/25/2009 | CN101394857A Composite for treating cancer containing oligonucleotide and nontoxic LPS |
| 03/25/2009 | CN101394856A Pharmaceutical latrunculin formulations |
| 03/25/2009 | CN101394855A Sterilized peritoneal dialysis solutions containing heparin |
| 03/25/2009 | CN101394854A Novel use of antihistamine agents for the preventive or early treatment of inflammatory syndromes, in particular those triggered by togaviruses |
| 03/25/2009 | CN101394853A Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders |
| 03/25/2009 | CN101394852A Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
| 03/25/2009 | CN101394851A Gsk-3 inhibitors for the treatment of osteoporosis |
| 03/25/2009 | CN101394850A Orodispersible domperidone tablets |
| 03/25/2009 | CN101394849A Stable dosage formulations of imidazolylalkyl-pyridines |
| 03/25/2009 | CN101394848A Use of vildagliptin for the treatment of diabetes |
| 03/25/2009 | CN101394847A Cycloalkylamines as monoamine reuptake inhibitors |
| 03/25/2009 | CN101394846A Treatment of atherosclerotic disease |
| 03/25/2009 | CN101394845A Extended cycle multiphasic oral contraceptive method |
| 03/25/2009 | CN101394844A Methoxypolyethylene glycol thioester chelate and uses thereof |
| 03/25/2009 | CN101394843A Improved treatment for anemia using a HIF-alpha stabilising agent |
| 03/25/2009 | CN101394837A Ezetimibe compositions |
| 03/25/2009 | CN101394834A Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues |
| 03/25/2009 | CN101394738A Compounds for the treatment of metabolic disorders |
| 03/25/2009 | CN101392251A Micro RNA capable of inducing stem cell to differentiate toward osteoblasts and use thereof |